Skip to main content

Table 1 Clinicopathological characteristics and follow-up data for 99 patients with BC

From: Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivotumor growth

Characteristics

Number of patients/Number analyzed (%)

Median age (range)

48 (30 to 74) (years)

Histological type*

 

   Ductal

93/99 (94%)

   Lobular

1/99 (1%)

   Other

5/99 (5%)

Histological grade*

 

   I

22/99 (22%)

   II

58/99 (58%)

   III

19/99 (20%)

Lymph node status at time of primary diagnosis

   Metastasis

57/99 (58%)

   No metastasis

42/99 (42%)

AJCC clinical stage**

 

   I

8/99 (8%)

   II

68/99 (69%)

   III

23/99 (23%)

Overall survival (median, range)

74 (6 to 112) (months)

   Alive without evidence of cancer

45/99 (68%)

   Alive with cancer

14/99 (14%)

   Died of cancer

40/99 (40%)

   Died of other disease

0/99 (0%)

  1. * According to the WHO classification of BC. ** According to the AJCC staging system; AJCC, American Joint Committee on Cancer; BC, breast cancer; WHO, World Health Organization.